Boston, Mass, Chapel Hill and Durham, NC, and Little Rock, Ark Background: Though peanut oral immunotherapy (OIT) is a promising investigational therapy, its potential is limited by substantial adverse events (AEs), which are relatively understudied. Objective: A retrospective analysis was conducted, pooling data from 3 pediatric peanut OIT trials, comprising the largest analysis of peanut OIT safety to date. Methods: We pooled data from 104 children with peanut allergy from 3 peanut OIT studies. We catalogued AEs from parental reports, daily symptom diaries, and dose escalations. We included events that were considered likely related to OIT and identified potential baseline predictors of higher AE rates using generalized linear regression models. Results: Eighty percent of subjects experienced likely related AEs during OIT (72% during buildup and 47% during maintenance). Of these AEs, over 90% occurred while at home. Approximately 42% of subjects experienced systemic reactions, and 49% experienced gastrointestinal symptoms. Twenty percent of subjects dropped out, with half (10% of the overall group) due to persistent gastrointestinal symptoms. Baseline allergic rhinitis (AR) and peanut SPT wheal size were significant predictors of higher overall AE rates. SPT wheal size predicted increased gastrointestinal AEs, and AR predicted increased systemic reactions. Over the course of OIT, 61% of subjects received treatment for likely related AEs, 59% with antihistamines and 12% with epinephrine. Conclusions: Peanut OIT is associated with frequent AEs, with rates declining over time, and most graded mild. However,
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Food allergy is a potentially life-threatening condition affecting approximately 3% to 8% of US children. [1] [2] [3] With no approved curative therapy, management is restricted to allergen avoidance and supportive measures if symptoms occur. 4, 5 A major focus of current research is the development of disease-modifying treatments that modulate the allergic immune response, protecting against accidental exposure. Oral immunotherapy (OIT) for peanut allergy has been shown to successfully desensitize a majority of children with peanut allergy, which has generated excitement about OIT for peanut allergy, but significant concerns remain regarding its safety. 6 Evaluating the safety profile, however, is complicated by the lack of detailed assessments of safety in larger sample sizes. Furthermore, OIT trials vary widely in both protocols and the methods used to present adverse events (AEs). The few studies focused on safety acknowledge that most reactions are mild or moderate, but risk for systemic reactions requiring epinephrine remains. [7] [8] [9] The goal of our study was to address this knowledge gap by: (1) characterizing the frequencies of OIT-associated AEs and study withdrawals, and (2) identifying baseline characteristics that may identify subjects at higher risk for AEs. Accordingly, we pooled data from 3 trials performed by the same group, examining both AEs in the research unit (ie, staff-observed) and AEs that occur at home, where parents must manage reactions without the support of clinical staff.
METHODS

Study design
In this retrospective analysis, we compiled data from 3 peanut OIT studies: the trial by Jones et al, an uncontrolled pilot study 10, 11 ; the study by Varshney et al, a randomized, placebo-controlled trial 12 ; and the DEVIL (Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance) study, an ongoing randomized single-center trial. See the Methods section and Table E1 in this article's Online Repository at www.jacionline.org for further details.
Safety data collection
Safety data were collected from 3 sources: records of symptoms occurring during dose escalation at the research unit, symptom diaries of home AEs, and parents' reports of home AEs. All analyses primarily focus on events that were 
Statistical methods
We computed means, SDs, frequencies, and proportions for all clinical history and immunologic variables. Statistical analyses were conducted using t-tests, x 2 tests, Fisher exact tests, or generalized linear regression modeling (see the Methods section in this article's Online Repository for details). For all analyses (unless specified otherwise), home and research unit AEs were grouped together to best represent the overall risk experienced by participants receiving OIT.
Ethical considerations
All of the trials were conducted in accordance with the principles of the Declaration of Helsinki. For the clinical trials from which these data were generated, ethics approval was obtained from the institutional review boards of the institutions involved. Written informed consent was obtained prior to participation, in accordance with each institution's ethics guidelines for pediatric research.
RESULTS
Subject demographics and participant flow
Of recruited subjects, 94% (104/111) tolerated the initial-day escalation and went on to have OIT administered at home (Fig 1) . The remaining 7 included 1 individual who passed the entry challenge, 2 who withdrew prior to initial escalation, and 4 who did not tolerate initial escalation. Of these 4, 2 had difficulties establishing intravenous access in preparation for the protocol, and 2 developed symptoms during the escalation itself (1 with asthma symptoms and 1 with severe abdominal pain and vomiting requiring epinephrine) (Fig 1) .
The final study cohort of 104 subjects consisted of a mostly white pediatric population with a slight male predominance (Table I) . A majority of subjects had other allergic diseases, including asthma (44%), atopic dermatitis (77%), and allergic rhinitis (AR) (46%). All subjects had a positive peanut SPT result, and 91 subjects (88%) also had an elevated peanut-specific IgE level (> _7 kU/L).
At the time of data extraction, approximately half of the study population had completed the protocol, and a third were still receiving OIT. Twenty-one subjects (20%) withdrew from OIT, 13 did so due to new-onset or worsening symptoms developing on OIT. The remainder withdrew because of logistic difficulty participating in the study. Of the 13 experiencing symptoms, 10 subjects (10% of the overall sample, and 77% of symptomatic withdrawals) dropped out due to new-onset persistent gastrointestinal symptoms (abdominal pain, emesis, and dysphagia), 1 due to worsening asthma, and 2 due to taste aversion. In the 10 who developed gastrointestinal symptoms, the mean presentation time of first gastrointestinal symptom was 17 days (range, 0-74 days); 3 patients were evaluated by means of esophagogastroduodenoscopy, and 2 had findings consistent with eosinophilic esophagitis (EoE). 13 
Characteristics and rates of AEs
Of the 106 subjects who underwent initial dose escalation, 85 (80%) developed at least 1 AE likely related to study treatment, and of the 104 who began buildup OIT, 83 (80%) developed at least 1 AE during their time on therapy (Fig 1) . A total of 1077 likely-related AEs were documented among these 83 participants (see Fig E1 in this article' s Online Repository at www.jacionline. org). Among all likely related AEs, 75 events (7%), affecting 35 subjects (34%), occurred during dose escalations in the research unit, while the remainder occurred at home (93%). The mean AE rate was 1.7% of dosing days (Table II) , with an annualized rate of 3.5. The mean AE rate was higher during the buildup phase than during the maintenance phase of treatment (P 5 .005). The percent of subjects affected by AEs decreased from buildup to maintenance as well (P < .001; Table II ). This decline in AE rates from buildup to maintenance occurred both among home AEs (P 5 .008) and research-unit events (P < .001).
A majority (85%) of the reactions were mild, 15% moderate, and zero severe (Table II) . Though these AEs comprised a variety of symptoms, most events involved a combination of skin, upper and lower respiratory, or gastrointestinal symptoms (26%; Fig 2) . The most common isolated symptoms were abdominal pain (16%), oral pruritus (16%), nausea/vomiting (9%), and nasal symptoms (8%).
Of all AEs, 113 events (10%) included symptoms indicative of a systemic reaction (as defined in the Methods section of this article's Online Repository), with higher rates during buildup (65 events; 0.3% of dosing days) than in maintenance (48 events; 0.06% of dosing days; P < .001). Of the 113 systemic reactions, 110 (97%) occurred at home, while only 3 (<1%) occurred at the research unit. Over the course of therapy, 44 subjects (42%) experienced a systemic reaction, with a rate of 0.3% of dosing days and an annualized rate of 0.37.
Of note, 51 subjects (49%) experienced gastrointestinal events at some time during therapy. Thirty-three percent of AEs (352/ 1077) included gastrointestinal symptoms, and 26% (281/1077) of AEs involved isolated gastrointestinal symptoms (including abdominal pain, nausea, vomiting, dysphagia, and diarrhea). The annualized rate of gastrointestinal reactions was 1.1.
Predictors of AEs
We found that the presence of AR and the wheal size of the peanut SPT were the only significant predictors of the overall rate of AEs, both before and after adjusting for sex, age, asthma, peanut-specific IgE, and atopic dermatitis (Table III) . After controlling for the other variables, the AE rate among subjects with AR was 2.9-fold higher than that in those without AR, and the rates of AEs increased by 1.4-fold for every 5-mm increase in peanut SPT wheal size (Table III) . Of note, the unadjusted models for all AEs showed similar results, with both AR and peanut SPT size as significant predictors of AE rate (see Table E2 in this article's Online Repository at www.jacionline.org).
Splitting the models by phase, we found that AR remained significantly associated with higher AE rates during both the buildup and maintenance phases, and the incidence rate ratio associated with AR was increased from 2.1 during buildup to 6.9 in the maintenance phase (Table III) . The SPT size was a significant predictor of AEs during the buildup phase, but there was only a nonsignificant trend in the maintenance phase. Also, while asthma was not significant in predicting rates of AEs overall, the presence of asthma was associated with significantly increased AE rates, by 2.3-fold, during maintenance (Table III) .
Analyzing the frequency of AEs by month revealed that among subjects without AR, AE rates were highest in January and September, whereas among subjects with AR, AE rates were highest in April and October (Fig 3) . The counts of AEs by month were statistically significantly different between the groups with and without AR (P 5 .001). Furthermore, among participants with AR, the risk for an AE occurring during a peak pollen month compared to a nonpeak month was 1.4-fold as high as that of the subjects without AR (95% CI, 1.1-1.8; P 5 .0013). This difference was driven largely by AEs occurring in the buildup phase (buildup risk ratio, 1.4; 95% CI, 1.0-1.9; P 5 .01).
Isolating the likely related events associated with systemic reactions, we determined that AR was the only significant predictor of the rate of systemic reactions, both before and (7) 72 (9) 3 (1) *Individual rates of AEs were calculated as the number of AEs divided by days on OIT, and averaged across all participants. Due to missing severity data for 3 events, the denominator used for the maintenance was n 5 291.
after adjusting for sex, age, asthma, peanut SPT wheal size, log peanut-specific IgE level, and atopic dermatitis. Rates of systemic AEs increased 2.2-fold (95% CI, 1.1-4.3; P 5 .03) for participants with AR compared to those without. Isolating the 352 events associated with gastrointestinal symptoms, we determined that the peanut SPT wheal size was the only significant predictor of the rate of gastrointestinal AEs, both before and after adjusting for sex, age, asthma, log peanutspecific IgE, atopic dermatitis, and AR. Rates of gastrointestinal AEs increased 1.8-fold (95% CI, 1.4-2.4; P < .001) for every 5-mm increase in SPT size.
Treatment administered for AEs
Over the course of OIT, 63 subjects (61%) were administered treatment for 240 (22%) likely related events (Table IV) . Seventeen of these events occurred in the research unit (7%), while the remaining 93% were managed at home. All AEs occurring in the research unit were managed with antihistamines alone, and epinephrine was never administered.
Antihistamines were administered most often, and while treatment with oral corticosteroids or epinephrine and emergency department (ED) visits occurred at similar rates, they did not always happen concurrently (Fig 4, A) . Twenty-two subjects (21%) experienced 40 events (4% of all AEs) in which they were administered albuterol, oral steroids, or visited an ED but were not administered epinephrine. All of the 18 events that resulted in epinephrine administration occurred at home. Four events included isolated skin symptoms; 1 event included isolated lower respiratory symptoms, 1 included isolated mild gastrointestinal symptoms, and the remaining 12 involved a combination of skin, respiratory, and gastrointestinal symptoms.
Examining parental patterns of epinephrine use in response to specific symptoms, we found that parents administered epinephrine for 3 of the events (43%) with moderate or severe cough, for 8 events (30%) with any severity of wheezing, and 2 of the events (25%) with whole-body hives (Fig 4, B) . However, they did not administer epinephrine for any of the 60 events with moderate to severe abdominal pain or vomiting (Fig 4, B) .
Furthermore, of the previously identified 113 systemic reactions, there were 97 events (9% of all AEs), affecting 40 subjects (38%), in which epinephrine was warranted but not administered. During 38 of these events (affecting 20 subjects), either albuterol or corticosteroids were given. Four of the subjects (4 separate events) went to the ED for treatment of their reaction. There were no hospitalizations or fatalities.
DISCUSSION
We present the largest-scale safety analysis of peanut OIT performed in a controlled research setting. This study revealed for the first time that AR and peanut SPT wheal size were both statistically and clinically significant predictors of the rates of AEs. Our findings predict that for 2 individuals with otherwise similar characteristics, an individual with AR might have 29 AEs for every 10 AEs in an individual without AR. AR was also predictive of higher rates of systemic reactions. The association of AEs and AR appears to be corroborated by a seasonality of AEs during the spring and fall in subjects with AR compared to those without AR, which to our knowledge is the first demonstration of this effect. This has implications for AE surveillance and the biology of allergen copriming.
Similarly, larger SPT size was also predictive more AEs overall, as well as gastrointestinal AEs overall. Other studies have identified baseline specific IgE as a predictor of higher rates of AEs or study withdrawal, but our study did not confirm this finding.
14 Furthermore, during maintenance, the presence of asthma at baseline was also predictive of a higher rates of AEs. This finding may have been due to the young age of many of the participants, who may later be officially diagnosed with asthma. A common concern has been that subjects with poorly controlled asthma have difficulties even during the buildup phase of OIT, but this concept could not be confirmed in the model. This analysis was also limited by the fact that patients with moderate to severe asthma are generally excluded from OIT trials for safety reasons.
If confirmed in other settings, it is possible that the presence of asthma or AR and SPT wheal size may be influential in identifying subjects likely to experience AEs on OIT. SPT size in particular may be useful in identifying the subjects with increased gastrointestinal AEs, who appear to be at greater risk for dropping out. This is especially important in generalizing to clinical settings the results of OIT performed in highly selected individuals.
Regarding the safety profile overall, despite differences in protocol and methods of reporting safety data, our rates of AEs appear to be consistent with those from prior studies. In our study, we found 80% of subjects reacting to OIT, while other estimates ranged from 86% to 100%, 9,15,16 and we found 47% of subjects reacting while on stable doses, compared with 54% in another study. 16 Our rate of 1.7% of dosing days with AEs was also similar, with one study demonstrating 2.6% of dosing days associated with AEs. 17 Our rate of study withdrawal was 20% (13% due to symptoms), which was equally high in other studies, from 5% to 36%. [16] [17] [18] One element in assessing the risk for OIT involves examining rates of AEs during OIT as well as those occurring during the standard of care (ie, strict allergen avoidance). This was not a prespecified objective of this study and is best done prospectively with rigorous design features (randomization, careful AE reporting, lengthy periods of follow-up). Thus, while we acknowledge that any such observation is potentially limited by methodologic differences, particularly in the way reactions were captured and J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 reported, the illustration may be helpful to put our findings into some context. Combining data from several assessments of the natural course of peanut allergy with strict allergen avoidance, 39% of subjects had a postdiagnosis peanut-induced reaction over a mean period of follow-up of approximately 5 years. [19] [20] [21] In our study, 80% of subjects experienced an OIT-induced reaction over a median of 2.8 years, though of note, our rate of reporting reactions may also be higher due to more rigorous AE capture methods. A 3-year prospective study of accidental allergic reactions in an observational cohort of 512 young children who were likely (but not confirmed) to have milk or egg allergy, found an annualized reaction rate of 0.81 per year to milk, egg, and peanut. 22 In contrast, our annualized reaction rate was over 400% higher, at 3.5 per year. Taken together, these data suggest that OIT-induced allergic reactions to the index food may occur more commonly than accidental reactions during avoidance, which would not be unexpected given the stimulation of the immune system inherent to OIT. However, most allergic AEs during OIT are mild and self-limited, resolving without permanent sequelae even when they necessitate treatment withdrawal. Assessing the relative risks of frequent mild reactions during OIT versus long-term protective benefits is an area that requires further study with extended periods of careful surveillance, especially among adolescents and young adults, the population most at risk for fatal anaphylaxis.
We defined systemic reactions using National Institutes of Allergy and Infectious Diseases/Food and Allergy Anaphylaxis Network 23 definitions of anaphylaxis and found that these occur at a high rate, with over 40% of participants experiencing at least 1 episode, and at least 38% of subjects experiencing events that may have warranted epinephrine use that was not given. This is particularly concerning, given that over 90% of likely related AEs occurred at home, emphasizing the importance of anaphylaxis education. Isolating specific symptoms that might trigger the use of epinephrine, we observed that families were more likely to administer epinephrine in response to respiratory symptoms than abdominal symptoms, though use of epinephrine still fell below 50%. Furthermore, at least 20% of subjects experienced an event necessitating treatment with albuterol or corticosteroids, or an ED visit, but in which epinephrine was not administered. Although allergic reactions are inherently complex and polymorphic, these findings suggest under-recognition or undertreatment, despite extensive education and around-theclock provider access. While comparisons of epinephrine use are limited by differences in treatment criteria, in our study, 12% of subjects overall received epinephrine (4% during buildup IRR, Incident rate ratio. *Statistically significant in the unadjusted models (see Table E2 in this article's Online Repository). and 11% during maintenance). This rate is higher than those from other research OIT trials, which varied from 0% to 2%, 15, 17, 18, 24 but were similar to those from a study of data from 5 clinical allergy practices, which described 12% of subjects requiring epinephrine during buildup and 6% during maintenance. 9 While our rates of epinephrine use are similar to some seen in other studies, our findings also suggest that epinephrine use is not an appropriate proxy for severity of reactions. Accordingly, we will need to develop new approaches for capturing the severity of reactions experienced by subjects on OIT. While reluctance to use epinephrine is well characterized among the population with food allergy overall, 22, 25 there has been relatively little study of whether and how this reluctance is affected by immunotherapy, a key area for future study.
The predominance of gastrointestinal AEs, combined with the high dropout rate from persistent gastrointestinal symptoms and the potential risk for EoE, does raise some concerns. Other studies have also reported high rates of gastrointestinal symptoms, [16] [17] [18] 24 and an increasingly recognized connection between OIT and iatrogenic EoE. 26, 27 Further quantifying this EoE risk is difficult because research volunteers are not commonly subjected to invasive diagnostic procedures like endoscopies, particularly prior to initiating OIT. Among symptomatic subjects receiving peanut OIT in a community practice setting, there was a substantially increased prevalence of EoE. 26 In our study, although 10 subjects withdrew due to gastrointestinal AEs, only 3 ultimately had an endoscopic evaluation, and 2 of these were diagnosed with EoE. At the time of publication, both were asymptomatic, but due to incomplete gastrointestinal follow-up, it is not clear whether these 2 patients had only temporary or longstanding EoE. Even so, our incidence rate of 648/100,000 person-years (2 subjects/308.8 person-years) is high compared with estimates of the incidence of pediatric EoE in the general population, at 10/100,000 person-years, 28 though this incidence among individuals with food allergy has not been well described and is potentially high as well. Taken together, these data suggest that current estimates of EoE during OIT of approximately 3% to 4% may be low and this requires more study. 27 We acknowledge that this study was limited by its retrospective nature and limited availability of placebo control data. While relatedness to OIT and severity of events were classified at the time of reporting, determination of which reactions were systemic and required epinephrine was made after the data were collected and may be limited by the information collected on diaries and therefore subject to bias. We also acknowledge that our methods for treating anaphylaxis may differ from other groups' recommendations. Finally, while this analysis benefited from pooling studies conducted by the same group and largely the same clinical providers, these subjects were enrolled over 9 years. Knowledge of which symptoms may be related to OIT has evolved, with greater recognition of the importance of gastrointestinal AEs. Therefore, among the earlier events, it is likely that symptoms such as isolated gastrointestinal symptoms may have been incorrectly classified as possibly related or unrelated, and therefore excluded from analysis based on our inclusion criteria. These limitations, however, suggest that the true rates of OITrelated AEs, in particular gastrointestinal events, may be even higher than we observed. (4) 26 (3) 20 (7) 22 (21) 11 (11) 15 (17) Epinephrine 18 (2) 4 (1) 14 (5) 12 (12) 4 (4) 10 (11) Corticosteroid 11 (1) 3 (<1) 8 (3) 7 (7) 3 (3) 6 (7) ED visit 18 (2) 5 (>1) 13 (5) 12 (12) 5 (5) 9 (10) Data are expressed as no. (%). Due to missing treatment data for 3 events, the denominator used for the maintenance was n 5 291.
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Summary
OIT for peanut allergy, while clearly efficacious in producing robust desensitization, continues to be limited by frequent AEs, with high AE rates likely exceeding the reaction rate expected during allergen avoidance. Gastrointestinal symptoms appear to dominate, accounting for a large proportion of study withdrawal, though these symptoms are ultimately self-limited. The high proportion of subjects experiencing systemic reactions raises concerns about the apparent reluctance of our participants to administer epinephrine when warranted. The findings from this analysis suggest that larger peanut SPT wheal sizes, AR (especially seasonal), and potentially asthma, may predict higher rates of AEs. Furthermore, larger SPT size is also predictive of higher rates of gastrointestinal side effects, highlighting a group that appears to be at greater risk for study withdrawal and EoE. While these results will need to be confirmed in larger-scale prospective, randomized, controlled clinical trials, the implications of our data are important and hypothesis generating. With validated predictors of risk, we could stratify individuals at high risk for AEs or treatment withdrawal, and thereby assist in the selection among multiple therapies for food allergy. Furthermore, these data support investigation into mechanistic links between OIT and gastrointestinal AEs and also aeroallergen exposure and food reactivity, methods for improving OIT safety by targeting comorbid allergic disease, as well as behavioral outcomes research of caregiver perceptions of anaphylaxis. Although OIT is a promising investigational therapy with the potential to improve food allergy associated mortality and quality of life, we have demonstrated a number of important safety variables that are both problematic and poorly understood. Additional studies beyond clinical trials (eg, outcomes research, biomarker studies) are needed in order to weigh the substantial potential benefits of OIT against the risks, harmonize patient-selection strategies, and move food allergy treatment into the realm of personalized medicine, all extremely important but beyond the scope of this article. In the short term we would advise awaiting the results of adequately powered, placebo-controlled trials before implementation into widespread practice, and suggest that, for now, allergen avoidance should remain the current standard of care. Clinical implications: Given high rates of OIT-related AEs, both systemic and gastrointestinal, additional safety studies are needed before implementation into widespread practice. Currently, allergen avoidance should remain the standard of care.
METHODS
Study designs and subject recruitment
We compiled data from 3 oral immunotherapy (OIT) studies conducted at Duke University Medical Center (DUMC), the University of North Carolina at Chapel Hill (UNC), and the University of Arkansas for Medical Sciences/ Arkansas Children's Hospital (ACH). The underlying objective of all 3 studies was to demonstrate the efficacy of peanut OIT in achieving desensitization in children allergic to peanuts and to determine whether sustained unresponsiveness could be achieved. The study by Jones et al E1,E2 (NCT01891136; n 5 39) was an uncontrolled pilot study of peanut OIT, while the study by Varshney et al E3 (NCT00815035; n 5 28) was a randomized, placebo-controlled trial of peanut OIT, with an open-label arm for all placebo subjects after 1 year. Both of these multicenter studies were conducted in collaboration between DUMC/ UNC and ACH. From these 2 studies, only data from participants enrolled at DUMC/UNC were used in the present analysis, and data collected spanned April 2004 to June 2013. Inclusion and exclusion criteria were as previously published. The third trial, the DEVIL (Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance) study (NCT00932828; n 5 49), is an ongoing randomized, single-center trial initially conducted at DUMC and later at UNC, comparing a low and high maintenance dose of peanut OIT, in patients with a younger age range of 9 to 36 months. Inclusion and exclusion criteria were similar for this study, with the exception of target age and the use of a positive result on oral food challenge on entry (Table E1) .
OIT protocol
OIT administration consisted of gradually escalating doses of allergen, administered orally in a food vehicle each day over months, with the goal of desensitization. Protocols of the studies by Jones et al and Varshney et al were as previously published, and the DEVIL study shares these protocols, with changes as described in Table E1. E1,E2 While the trials varied in study design (Table E1) , they all shared the same features in terms of dose escalation, comprising 3 phases: initial escalation day, buildup with clinic visits every 2 to 3 weeks, and maintenance. Buildup lasted approximately 1 year, though this duration varied by subject. Doses were increased in this fashion until the goal maintenance dose, which ranged from 300 to 4000 mg of peanut protein, depending on the study, was achieved (Table E1) . At this point, the maintenance phase was begun, in which subjects continued to take the maintenance dose on a daily basis for approximately 3 to 4 years.
Safety data collection
Safety data were collected in 3 different ways: (1) records of symptoms occurring during dose escalation at the clinic, (2) symptom diaries of AEs that occurred at home, and (3) reports of AEs occurring at home based on patient interview. During dose escalation, research staff recorded the symptoms and timing of all AEs, as well as treatment administered. With doses administered at home, parents recorded any symptoms typically associated with allergic reactions, such as rash, mouth itch, sneezing, coughing, vomiting, and diarrhea, in daily symptom diaries, along with the timing of the event and the treatment administered. Furthermore, parents were instructed to report all events, whether perceived as related or unrelated, to study coordinators, in order to capture all events potentially associated with therapy. These reported events were catalogued in an AE database (MS Access). All events were evaluated by study personnel at the time of occurrence for their possible relatedness to the therapy, based on the timing and characteristics of symptoms, and assigned 1 of 3 possible relationships to OIT: likely related, possibly related, or unrelated. All analyses were primarily focused on events that were deemed likely related to therapy after subjects had tolerated the initial escalation day. We did not include any symptoms occurring during the food challenges that were part of the screening process or required for testing desensitization or sustained unresponsiveness.
Treatment of reactions at home
The families of all study participants received extensive standard-of-care teaching in the recognition and treatment of allergic reactions and anaphylaxis. Subjects or their caregivers were instructed to administer an antihistamine for any mild reactions (generally only affecting 1 body system) that developed within 2 hours of dosing. Reactions that involved more than 1 body system or that were associated with systemic symptoms were considered to be moderate or severe, and subjects/caregivers were advised to administer epinephrine promptly and to call 911 for emergency assistance. The study team ensured that all families had in-date epinephrine autoinjectors and food allergy action plans. A study physician was available by pager and phone at all times throughout the study, and parents were strongly encouraged to call with any questions about a given reaction.
Statistical methods
We computed means, SDs, frequencies, and percentages for all clinical history and immunologic variables. Comparisons were made by t-tests or paired t-tests, and x 2 tests or Fisher exact tests where appropriate. AE reports, symptom diary reports, and reactions during dose escalations were compiled for all subjects who received OIT, in order to generate counts and rates of likely related events experienced by every individual during the buildup phase, during the maintenance phase, and in total. For all analyses (unless specified otherwise), home AEs and research unit AEs were grouped together to best represent the overall risk experienced by participants receiving OIT. Based on the descriptions and symptoms reported, we retrospectively sorted events into a variety of categories, and the multiple-symptoms category was reserved for events that included more than 1 allergic symptom.
Some subjects from the study by Varshney et al were originally enrolled in a placebo arm and then transferred to an open-label section of this trial after 1 year. Events during these placebo periods were not included, but events from the open-label period were included in the analysis. Because the number of subjects who received placebo (8 of the original 111 subjects) and time on placebo (1 year for each subject) were limited, we did not formally compare the treatment group to the placebo group.
We assessed the baseline predictors of AE outcomes (sex; age at starting therapy, as a continuous variable; current and past history of asthma, atopic dermatitis, or AR; baseline peanut IgE level; and baseline peanut SPT wheal size) using principal component analysis, finding no collinearity that would require removal of a particular variable. These variables were chosen based on their clinical relevance. We then fit a generalized linear model, assuming a Poisson distribution with scaled deviance, to determine the influence of the covariates listed above on the counts of AEs. These Poisson models were fit with and without adjusting for the other covariates. Because each individual may spend a different duration of time on therapy, we used the time on therapy on a log scale as an offset to adjust for this variable exposure to OIT. We then fit a similar Poisson model for AEs during the buildup period as well as AEs during the maintenance period to determine whether there were any differences between the phases. Finally, we fit a Poisson model focusing solely on any AEs that involved gastrointestinal symptoms, and another focusing on systemic reactions. From these models, we presented the incidence rate ratios for each of the variables, after adjusting for the other covariates in the model. For the covariates studied, missing data were limited. For 1 subject, baseline IgE was missing, and this value was imputed with the month-3 IgE.
To assess seasonality of AEs between subjects with and without AR, we calculated the proportion of AEs occurring in each month. The X 2 test was used for determining whether the counts of AEs by month were different between subjects with AR and those without. Relative risk ratio was calculated using rates of AEs during peak allergy months (April and September) compared with nonpeak months (December).
To assess whether an event was indicative of a systemic reaction, we developed the following algorithm, based on the criteria for anaphylaxis established by the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network symposium. E4 At the time that the AE was reported, each individual symptom was graded by the participants on a 3-point scale of mild (1), moderate (2), or severe (3) . If an AE involved wheezing (mild, moderate, or severe), severe angioedema, whole-body hives (severe), cough (moderate or severe), or repeated vomiting (moderate or severe), or involved at least 2 body systems, then the event was labeled as a systemic reaction. For this analysis, we assumed that all systemic reactions should have been treated with epinephrine, and we compared this predicted risk for epinephrine use to the actual rate of epinephrine use.
Of note, reactions were also evaluated for their overall severity (based on the individual symptom severities assigned), and grouped into mild, moderate, and severe categories. Severe AEs were defined as involving hospitalization, intensive care unit admission, or documented hypotension.
To assess parental patterns of epinephrine use, we identified 5 isolated symptoms that might have triggered the use of epinephrine: moderate or severe coughing, wheezing of any severity, severe hives, and moderate or severe abdominal pain or vomiting. We then determined the percentage of cases in which epinephrine was given in response to an event involving any of these symptoms.
All statistical analyses were performed with Stata/SE 13.1 (StataCorp LP, College Station, Tex) and SAS 9.3 (SAS Institute, Cary, NC). 
